皮肤鳞状细胞癌的当前治疗景观
The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma
影响因子:8.80000
分区:医学1区 Top / 皮肤病学1区
发表日期:2023 Jan
作者:
Chia Yuen Chong, Michelle S Goh, Sandro V Porceddu, Danny Rischin, Annette M Lim
摘要
非黑色素瘤皮肤癌（NMSC）是全球皮肤癌最常见的形式。皮肤鳞状细胞癌（CSCC）的全球发病率正在上升，估计在2019年诊断出240万例病例。长期暴露于紫外线（UV）辐射是发展CSCC的主要危险因素。大多数早期CSCC通过手术或放射疗法成功治疗。但是，局部晚期或转移性疾病可能与显着的发病率或死亡率有关。最近，通过引入免疫疗法的治疗范式已经彻底改变了耐用的癌症控制率，并可以实现约50％的缓解率，并显着改善了生活质量。自2018年以来，随着针对促进性死亡-1（PD-1）靶向药物的监管批准，现在将免疫疗法视为晚期或转移性CSCC上一线全身治疗的护理标准。
Abstract
Non-melanoma skin cancers (NMSCs) are the most common form of skin cancer worldwide. The global incidence of cutaneous squamous cell carcinoma (CSCC) is rising, with an estimated 2.4 million cases diagnosed in 2019. Chronic exposure to ultraviolet (UV) radiation is a major risk factor for developing CSCC. Most early-stage CSCCs are treated successfully with surgery or radiotherapy; however, locally advanced or metastatic disease can be associated with significant morbidity or mortality. Recently, the treatment paradigm for advanced CSCC has been revolutionised by the introduction of immunotherapy, which can achieve a response rate of approximately 50% with durable cancer control, and significant improvement in quality of life. With the regulatory approval of programmed death-1 (PD-1)-targeting drugs since 2018, immunotherapy is now recognised as the standard of care for first-line systemic therapy in advanced or metastatic CSCC.